NeuroPace (NPCE) Net Income towards Common Stockholders (2020 - 2026)
NeuroPace's (NPCE) quarterly Net Income towards Common Stockholders came in at -$22.0 million in Q1 2026, down 235.17% year-on-year from $16.3 million in Q1 2025, and down 470.42% quarter-over-quarter from -$3.9 million in Q4 2025.
NeuroPace (NPCE) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
NeuroPace's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$22.0 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 235.17% year-over-year to -$22.0 million in Q1 2026; TTM through Mar 2026 was -$52.8 million, a 110.36% decrease from a year earlier, with the FY2025 full-year figure at -$36.0 million, up 62.79% from the prior year.
- Net Income towards Common Stockholders slipped to -$22.0 million in Q1 2026 per NPCE's latest filing, from -$3.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$3.9 million in Q4 2025 and bottomed at -$22.0 million in Q1 2026.
- The 5-year median for Net Income towards Common Stockholders is -$9.0 million (2024), against an average of -$9.8 million.
- Across the five-year window, Net Income towards Common Stockholders jumped 41.55% in 2023 and plunged 235.17% in 2026, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$11.0 million in 2022, then soared by 41.55% to -$6.4 million in 2023, then grew by 19.55% to -$5.2 million in 2024, then advanced by 25.54% to -$3.9 million in 2025, then plunged by 470.42% to -$22.0 million in 2026.
- Per Business Quant, the three latest NPCE Net Income towards Common Stockholders figures stand at -$22.0 million (Q1 2026), -$3.9 million (Q4 2025), and -$5.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.85 Bn | 176.55 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.90 Bn | 126.02 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.55 Bn | 99.33 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.56 Bn | 67.10 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.24 Bn | 44.57 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.40 Bn | 27.28 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 28.15 Bn | 25.87 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.75 Bn | 21.63 Bn | 2.07 Bn | 176.78 Mn |
| 10 | NeuroPace | 516.54 Mn | 462.56 Mn | 18.05 Mn | -21.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.97 Mn |
| Dec 31, 2025 | -3.85 Mn |
| Sep 30, 2025 | -4.99 Mn |
| Jun 30, 2025 | -21.96 Mn |
| Mar 31, 2025 | -6.55 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Sep 30, 2024 | -5.69 Mn |
| Jun 30, 2024 | -7.67 Mn |
| Mar 31, 2024 | -9.02 Mn |
| Dec 31, 2023 | -6.43 Mn |
| Sep 30, 2023 | -7.37 Mn |
| Jun 30, 2023 | -9.25 Mn |
| Mar 31, 2023 | -9.56 Mn |
| Dec 31, 2022 | -11.00 Mn |
| Sep 30, 2022 | -11.68 Mn |
| Jun 30, 2022 | -12.61 Mn |
| Mar 31, 2022 | -11.46 Mn |
| Dec 31, 2021 | -11.50 Mn |
| Sep 30, 2021 | -7.93 Mn |
| Jun 30, 2021 | -6.38 Mn |